

**Summary of Community decisions on marketing authorizations in respect of medicinal products
from 15/05/2004 to 15/06/2004**

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

(2004/C 166/02)

**Issuing of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93)
Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
01.06.2004	Levemir	Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd,	EU/01/04/278/001-009	04.06.2004
04.06.2004	Abilify	Otsuka Pharmaceutical Europe Ltd, Common-wealth House, 2 Chalkhill Road, Hammersmith, London W6 8DW, United Kingdom	EU/1/04/276/001-020	08.06.2004
08.06.2004	TachoSil	Nycomed Austria GMBH, St.-Peter-Strasse 25, A-4020 Linz,	EU/1/04/277/001-004	11.06.2004
15.06.2004	Oxybutynin	Nicobrand Limited, 189 Casteroe Road, Coleraine, Northerne Ireland	EU/1/03/270/001-002	18.06.2004

**Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93)
Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
19.05.2004	Protopic	Fujisawa GmbH, Neumarkter Str. 61, D-81673 München,	EU/1/02/201/001-006	25.05.2004
25.05.2004	Hepsera	Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom	EU/1/03/251/001	27.05.2004
26.05.2004	Viagra	Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/98/077/001-012	01.06.2004
26.05.2004	Combivir	Glaxo Group Ltd., Greenford Road, Greenford, Middlesex UB6 0NN United Kingdom	EU/1/98/058/001-002	01.06.2004
26.05.2004	Ziagen	Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/99/112/001-002	01.06.2004

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
26.05.2004	Taxotere	Aventis Pharma S.A., 20 avenue Raymond Aron, 92165 Antony Cedex, France	EU/1/95/002/001-002	01.06.2004
26.05.2004	TRIZIVIR	Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/00/156/001-003	01.06.2004
01.06.2004	Vivanza	Bayer AG, D-51368 Leverkusen,	EU/1/03/249/001-012	07.06.2004
01.06.2004	Levitra	Bayer AG, D-51368 Leverkusen,	EU/1/03/248/001-012	07.06.2004
01.06.2004	Epivir	Glaxo Group Ltd., Greenford Road, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/96/015/001-005	07.06.2004
08.06.2004	Remicade	Centocor B.V., Einsteinweg 101, 2333 CB Leiden, Nederland	EU/1/99/116/001-003	10.06.2004
08.06.2004	Remicade	Centocor B.V., Einsteinweg 101, 2333 CB Leiden, Nederland	EU/1/99/116/001-003	10.06.2004
08.06.2004	Fuzeon	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/03/252/001-003	10.06.2004
08.06.2004	Arava	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main,	EU/1/99/118/001-010/	18.06.2004
08.06.2004	Vfend	Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/02/212/001-026	10.06.2004
09.06.2004	Vfend	Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/02/212/001-026	11.06.2004
10.06.2004	Arava	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main,	EU/1/99/118/001-010/	16.06.2004
10.06.2004	Viread	Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom	EU/1/01/200/001	14.06.2004

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
10.06.2004	Viread	Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom	EU/1/01/200/001	15.06.2004
10.06.2004	Herceptin	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/00/145/001	14.06.2004
10.06.2004	Humira	Abbott Laboratories Ltd., Queenborough, Kent ME11 5EL, United Kingdom	EU/1/03/256/001-006	14.06.2004
10.06.2004	Trudexa	Abbott Laboratories Ltd., Queenborough, Kent ME11 5EL, United Kingdom	EU/1/03/257/001-006	14.06.2004
15.06.2004	Xigris	Eli Lilly Nederland B.V., Grootslag 1-5, 3991 RA Houten, Nederland	EU/1/02/225/001-002	17.06.2004